Fulvestrant: Fulvestrant is a selective estrogen receptor degrader (SERD). It binds to estrogen receptors on breast cancer cells, blocking the effects of estrogen, which is a hormone that can promote the growth of breast cancer cells. Additionally, Fulvestrant leads to the degradation of the estrogen receptors, further reducing the ability of cancer cells to grow.

• Dosage: Follow the dosage and schedule prescribed by your oncologist.
• Typically, Fulvestrant is administered as an intramuscular injection (into the muscle) in the buttocks.
• Administration: Fulvestrant is administered by a healthcare professional, usually in a hospital or clinic setting.
• The typical dosing schedule is an initial dose followed by a second dose two weeks later, and then once monthly thereafter.

• Inform your doctor if you have any known allergies to Fulvestrant or other medications, or if you have bleeding disorders, liver problems, or low platelet counts.
• Discuss with your doctor if you have any underlying health conditions, particularly liver disease, bleeding disorders, or thrombocytopenia.

• Helps slow the progression of hormone receptor-positive breast cancer.
• Effective in patients who have become resistant to other forms of hormone therapy.
• Provides an additional treatment option for managing advanced breast cancer.

• Pain at the injection site
• Nausea
• Fatigue
• Hot flashes
• Joint or muscle pain
• Headache
• Increased liver enzymes
• Weakness
• Severe allergic reactions (rash, itching, swelling, severe dizziness, difficulty breathing)
• Blood clotting issues
• Liver problems